Literature DB >> 19187919

Relationship between right cervical vagus nerve stimulation and atrial fibrillation inducibility: therapeutic intensities do not increase arrhythmogenesis.

Youhua Zhang1, Itamar Ilsar, Hani N Sabbah, Tamir Ben David, Todor N Mazgalev.   

Abstract

BACKGROUND: Strong vagus nerve stimulation (VNS) is routinely used to induce and maintain atrial fibrillation (AF) in acute animal studies. Taken as a surrogate of increased vagal tone, such observations suggest an arrhythmogenic role of VNS in AF. In contrast, VNS has been demonstrated to have profound therapeutic effects in heart failure and other ailments.
OBJECTIVE: The purpose of this study was to examine the relationship between right cervical VNS and AF, especially the potential arrhythmogenic effects of therapeutic VNS.
METHODS: The relationship between VNS intensities and AF inducibility was studied in eight acute dogs at baseline and four different levels of VNS, which were set to prolong spontaneous sinus cycle length (SCL) by 20%, 40%, 60%, or 100%. The effect of mild VNS treatment on AF induction was further investigated in six chronically instrumented conscious dogs. These dogs were implanted with right cervical VNS stimulators and specialized atrial pacemakers. VNS intensity was titrated to slow the sinus rate by 10%.
RESULTS: In acute studies, it was found that mild to moderate VNS (i.e., producing < or =40% SCL prolongation) did not increase AF inducibility, while strong VNS (i.e., producing > or =60% SCL prolongation) did. In chronic studies, compared with controls, AF induction did not change during the 4-week VNS treatment.
CONCLUSIONS: AF inducibility by right cervical VNS is intensity dependent: strong VNS (producing > or =60% SCL prolongation) facilitates AF, while moderate VNS (producing < or =40% SCL prolongation) appears not to affect AF. The nonarrhythmogenic effect of therapeutic chronic VNS was further verified in conscious animals. We conclude that VNS with moderate intensities can be used to deliver therapeutic benefits without arrhythmogenic risk.

Entities:  

Mesh:

Year:  2008        PMID: 19187919     DOI: 10.1016/j.hrthm.2008.10.043

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  19 in total

Review 1.  New approaches for treating atrial fibrillation: Focus on autonomic modulation.

Authors:  Daniel Sohinki; Stavros Stavrakis
Journal:  Trends Cardiovasc Med       Date:  2019-10-31       Impact factor: 6.677

2.  Device-based autonomic modulation in arrhythmia patients: the role of vagal nerve stimulation.

Authors:  William A Huang; Kalyanam Shivkumar; Marmar Vaseghi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-05

3.  Acute ivabradine treatment reduces heart rate without increasing atrial fibrillation inducibility irrespective of underlying vagal activity in dogs.

Authors:  Kazunori Uemura; Masashi Inagaki; Can Zheng; Toru Kawada; Meihua Li; Masafumi Fukumitsu; Masaru Sugimachi
Journal:  Heart Vessels       Date:  2016-11-14       Impact factor: 2.037

4.  Vagal stimulation targets select populations of intrinsic cardiac neurons to control neurally induced atrial fibrillation.

Authors:  Siamak Salavatian; Eric Beaumont; Jean-Philippe Longpré; J Andrew Armour; Alain Vinet; Vincent Jacquemet; Kalyanam Shivkumar; Jeffrey L Ardell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-09-02       Impact factor: 4.733

5.  Continuous low-level vagus nerve stimulation reduces stellate ganglion nerve activity and paroxysmal atrial tachyarrhythmias in ambulatory canines.

Authors:  Mark J Shen; Tetsuji Shinohara; Hyung-Wook Park; Kyle Frick; Daniel S Ice; Eue-Keun Choi; Seongwook Han; Mitsunori Maruyama; Rahul Sharma; Changyu Shen; Michael C Fishbein; Lan S Chen; John C Lopshire; Douglas P Zipes; Shien-Fong Lin; Peng-Sheng Chen
Journal:  Circulation       Date:  2011-05-09       Impact factor: 29.690

Review 6.  Arrhythmias and vagus nerve stimulation.

Authors:  Youhua Zhang; Todor N Mazgalev
Journal:  Heart Fail Rev       Date:  2011-03       Impact factor: 4.214

7.  TREAT AF (Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation): A Randomized Clinical Trial.

Authors:  Stavros Stavrakis; Julie A Stoner; Mary Beth Humphrey; Lynsie Morris; Adrian Filiberti; Justin C Reynolds; Khaled Elkholey; Isma Javed; Nicholas Twidale; Pavel Riha; Subha Varahan; Benjamin J Scherlag; Warren M Jackman; Tarun W Dasari; Sunny S Po
Journal:  JACC Clin Electrophysiol       Date:  2020-01-29

Review 8.  Chronic functional bowel syndrome enhances gut-brain axis dysfunction, neuroinflammation, cognitive impairment, and vulnerability to dementia.

Authors:  Mak Adam Daulatzai
Journal:  Neurochem Res       Date:  2014-03-04       Impact factor: 3.996

9.  Inhibition of atrial fibrillation by low-level vagus nerve stimulation: the role of the nitric oxide signaling pathway.

Authors:  Stavros Stavrakis; Benjamin J Scherlag; Youqi Fan; Yu Liu; Jun Mao; Vandana Varma; Ralph Lazzara; Sunny S Po
Journal:  J Interv Card Electrophysiol       Date:  2012-11-20       Impact factor: 1.900

Review 10.  Translational neurocardiology: preclinical models and cardioneural integrative aspects.

Authors:  J L Ardell; M C Andresen; J A Armour; G E Billman; P-S Chen; R D Foreman; N Herring; D S O'Leary; H N Sabbah; H D Schultz; K Sunagawa; I H Zucker
Journal:  J Physiol       Date:  2016-06-17       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.